0001479290-21-000035.txt : 20210204
0001479290-21-000035.hdr.sgml : 20210204
20210204211557
ACCESSION NUMBER: 0001479290-21-000035
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210202
FILED AS OF DATE: 20210204
DATE AS OF CHANGE: 20210204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schilke Tobin
CENTRAL INDEX KEY: 0001678984
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 21593106
MAIL ADDRESS:
STREET 1: 7000 SHORELINE COURT, #371
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 1001
CITY: NASHVILLE
STATE: TN
ZIP: 37203
BUSINESS PHONE: 510-742-3400
MAIL ADDRESS:
STREET 1: 7555 GATEWAY BLVD
CITY: NEWARK
STATE: CA
ZIP: 94560
4
1
wf-form4_161249134328472.xml
FORM 4
X0306
4
2021-02-02
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001678984
Schilke Tobin
C/O REVANCE THERAPEUTICS, INC.
1222 DEMONBREUN STREET, SUITE 1001
NASHVILLE
TN
37203
0
1
0
0
CFO
Common Stock
2021-02-02
4
A
0
22620
0
A
71419
D
Employee Stock Option (Right to Buy)
28.01
2021-02-02
4
A
0
40925
0
A
2031-02-01
Common Stock
40925.0
40925
D
The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from March 15, 2021, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2021, subject to Mr. Schilke's Continuous Service (as defined in the Plan) on each vesting date.
/s/ Gordon Ho, Attorney-in-Fact
2021-02-04